Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fovista + Avastin versus Avastin alone in wet age-related macular degeneration
NL-OMON43730Phase 2Active, not recruiting
- Sponsor
- IVERIC bio
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pegpleranib and bevacizumab in exudative macular degeneration, sponsored by IVERIC bio. Started Mar 2016; status: active, not recruiting.
02
Drugs
pegpleranibbevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON43730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43730.